Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue.

Autor:	Litchfield K; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK., Stanislaw S; Roche Tissue Diagnostics, 1910 E. Innovation Park Drive, Tucson, AZ 85755, USA., Spain L; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK; Renal and Skin Units, The Royal Marsden Hospital, London SW3 6JJ, UK., Gallegos LL; Roche Tissue Diagnostics, 1910 E. Innovation Park Drive, Tucson, AZ 85755, USA., Rowan A; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK., Schnidrig D; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK., Rosenbaum H; Roche Sequencing Solutions, Madison, 500 S. Rosa Road, Madison, WI 53719, USA., Harle A; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK; Université de Lorraine, CNRS UMR 7039 CRAN, Institut de Cancérologie de Lorraine, Service de Biopathologie, 54000 Nancy, France., Au L; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK; Renal and Skin Units, The Royal Marsden Hospital, London SW3 6JJ, UK., Hill SM; Roche Tissue Diagnostics, 1910 E. Innovation Park Drive, Tucson, AZ 85755, USA; Department of Cancer Biology, University of Arizona Cancer Center, Tucson, AZ 85724, USA., Tippu Z; Renal and Skin Units, The Royal Marsden Hospital, London SW3 6JJ, UK., Thomas J; Renal and Skin Units, The Royal Marsden Hospital, London SW3 6JJ, UK., Thompson L; The Centre for Molecular Pathology, The Royal Marsden Hospital, London SW3 6JJ, UK., Xu H; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK., Horswell S; Department of Bioinformatics and Biostatistics, The Francis Crick Institute, London NW1 1AT, UK., Barhoumi A; Roche Tissue Diagnostics, 1910 E. Innovation Park Drive, Tucson, AZ 85755, USA., Jones C; Roche Tissue Diagnostics, 1910 E. Innovation Park Drive, Tucson, AZ 85755, USA., Leith KF; Roche Tissue Diagnostics, 1910 E. Innovation Park Drive, Tucson, AZ 85755, USA., Burgess DL; Roche Sequencing Solutions, Madison, 500 S. Rosa Road, Madison, WI 53719, USA., Watkins TBK; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK., Lim E; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK., Birkbak NJ; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK; Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark., Lamy P; Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark., Nordentoft I; Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark., Dyrskjøt L; Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark., Pickering L; Renal and Skin Units, The Royal Marsden Hospital, London SW3 6JJ, UK., Hazell S; Histopathology Department, Royal Marsden NHS Foundation Trust, London and Sutton, UK., Jamal-Hanjani M; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK; Department of Medical Oncology, University College London Hospitals, London, UK., Larkin J; Renal and Skin Units, The Royal Marsden Hospital, London SW3 6JJ, UK., Swanton C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK; Department of Medical Oncology, University College London Hospitals, London, UK. Electronic address: charles.swanton@crick.ac.uk., Alexander NR; Roche Tissue Diagnostics, 1910 E. Innovation Park Drive, Tucson, AZ 85755, USA. Electronic address: nelson.alexander@roche.com., Turajlic S; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK; Renal and Skin Units, The Royal Marsden Hospital, London SW3 6JJ, UK. Electronic address: samra.turajlic@crick.ac.uk.
Jazyk:	angličtina
Zdroj:	Cell reports [Cell Rep] 2020 May 05; Vol. 31 (5), pp. 107550.
DOI:	10.1016/j.celrep.2020.107550
Abstrakt:	Although thousands of solid tumors have been sequenced to date, a fundamental under-sampling bias is inherent in current methodologies. This is caused by a tissue sample input of fixed dimensions (e.g., 6 mm biopsy), which becomes grossly under-powered as tumor volume scales. Here, we demonstrate representative sequencing (Rep-Seq) as a new method to achieve unbiased tumor tissue sampling. Rep-Seq uses fixed residual tumor material, which is homogenized and subjected to next-generation sequencing. Analysis of intratumor tumor mutation burden (TMB) variability shows a high level of misclassification using current single-biopsy methods, with 20% of lung and 52% of bladder tumors having at least one biopsy with high TMB but low clonal TMB overall. Misclassification rates by contrast are reduced to 2% (lung) and 4% (bladder) when a more representative sampling methodology is used. Rep-Seq offers an improved sampling protocol for tumor profiling, with significant potential for improved clinical utility and more accurate deconvolution of clonal structure. Competing Interests: Declaration of Interests S.T. reports grants from Roche Tissue Diagnostics. K.L., S.T., and C.S. report speaker fees from Roche Tissue Diagnostics. K.L., S.S., S.T., and N.R.A. report a patent pending using Rep-Seq profiling to support detection of MRD. N.R.A., S.S., L.G., A.B., K.F.L., and S.H. have patents pending on representative sampling of solid tumors. C.S. receives grant support from Pfizer, AstraZeneca (AZ), Bristol-Myers Squibb (BMS), Roche-Ventana, Boehringer Ingelheim, and Ono. C.S. has consulted for Pfizer, Novartis, GlaxoSmithKline (GSK), Merck Sharpe & Dohme (MSD), BMS, Celgene, AZ, Illumina, Genentech, Roche-Ventana, GRAIL, Medicxi, and the Sarah Cannon Research Institute. C.S. is a shareholder of Apogen Biotechnologies, Epic Bioscience, and GRAIL and has stock options in and is co-founder of Achilles Therapeutics. Outside of the submitted work, K.L., S.T., and C.S. have a patent pending on indel burden and CPI response and a patent pending on targeting of frameshift neoantigens for personalized immunotherapy. J.L. reports institutional research support from BMS, MSD, Novartis, Pfizer, Achilles Therapeutics, Roche, Nektar Therapeutics, Covance, Immunocore, Pharmacyclics, and Aveo and consultancy support from Achilles, AZ, Boston Biomedical, BMS, Eisai, EUSA Pharma, GSK, Ipsen, Imugene, Incyte, iOnctura, Kymab, Merck Serono, MSD, Nektar, Novartis, Pierre Fabre, Pfizer, Roche/Genentech, Secarna, and Vitaccess. S.T. has received speaking fees from Astra Zeneca, Novartis, and Ipsen. S.T., K.L., and C.S. have the following patents filed: Clear Cell Renal Cell Carcinoma BiomarkersP113326GB. (Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu